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Abstract
Extended-spectrum b-lactamase (ESBL) -producing Enterobacteriaceae have been notiﬁable according to the Swedish Communicable
Disease Act since 2007. A major increase in the number of cases has been observed, with 2099 cases in 2007 and 7225 cases in 2012. The
majority of the isolates are Escherichia coli. Additionally, Swedish data on the prevalence of ESBL-producing invasive isolates of E. coli are
available through EARS-Net, and through biannual point prevalence studies, where molecular characterization of isolates from the entire
country is carried out. This paper describes major trends in the Swedish epidemiology of ESBL-producing E. coli in the period 2007–2012.
Isolates from the point prevalence studies were subjected to antimicrobial susceptibility testing, ESBL genotyping, pulsed-ﬁeld gel
electrophoresis, multi-locus sequence typing and phylogenetic grouping with PCR. The distribution of sequence types, resistance genes and
susceptibility levels were all stable over the three study periods. The dominating resistance gene conferring ESBL was blaCTX-M-15, found in
54–58% of the isolates. ST131 represented 34–38% of the isolates. Other major sequence types were ST38, ST69, ST405, ST617 and ST648,
each representing 2–6% of the isolates. Phylogenetic group B2 was the most common, and was observed in 41–47% of the isolates.
However, among ST131 isolates the B2 phylogenetic group represented 90–98% of the isolates. The most important epidemiological
difference seen over time was that the median age of infected women decreased from 62 to 52 years (p <0.0001) and infected men from 67
to 64 years. A potential explanation might be the shift towards a higher proportion of community-acquired infections in individuals lacking
comorbidities.
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Introduction
Extended-spectrum b-lactamase (ESBL) -producing Enterobac-
teriaceae (EPE) are increasing rapidly all over Europe. In
Sweden, all cases of EPE have been notiﬁable according to the
Communicable Disease Act since February 2007. The system-
atic reporting to the surveillance system SmiNet, which is
monitored by the Swedish Institute for Communicable Disease
Control (SMI), has resulted in a large and comprehensive
national data set covering a period of more than 5 years. The
number of reports to SmiNet has been steadily increasing,
from 2099 cases in 2007 (February–December) to 7225 cases
in 2012 (http://www.smittskyddsinstitutet.se/in-english/statis
tics/extended-spectrum-beta-lactamase-esbl/ last accessed 11
May 2013).
Other sources of systematic surveillance data are the
Swedish EARS-Net data, with susceptibility data for invasive
isolates of Escherichia coli and Klebsiella pneumoniae derived
from laboratories covering approximately 80% of the popula-
tion in Sweden, and the biannual point prevalence surveys
conducted by SMI, in which isolates were collected from most
clinical laboratories in Sweden. Such collections are available
from 2007, 2009 and 2011, and provide possibilities of detailing
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not only baseline epidemiology, but also in-depth analysis of
circulating clinical isolates.
At present, EPE are a growing threat to public health. These
bacteria constitute a burden on healthcare systems, conferring
excess mortality and prolonging hospital stays [1]. A major
reason for the increase of ESBL-producing E. coli is the
worldwide expansion of the successful clone sequence type
131 (ST131), often associated with blaCTX-M. Elevated viru-
lence of ST131 strains has been discussed but the evidence is
not clear. In a zebraﬁsh model Lavigne et al. [2] described
decreased virulence and improved persistence during infection
in CTX-M-producing ST131 and non CTX-M-producing ST131
compared with non-ST131 E. coli, which could be the key for
the great success of this clone.
In other Swedish studies the ESBL epidemiology in different
settings and in different geographic areas has been described.
Helldal et al. [3] described the prevalence of ESBL-producing
E. coli in southwestern Sweden during 2004–2008 with a
higher increase in nosocomially acquired isolates in compar-
ison to community-acquired, 0.2–2.5% and 0.2–1.6%, respec-
tively. A study from the county of €Osterg€otland indicated an
increased prevalence of EPE from 2002 to 2007, yet the
numbers were very low (<1%) [4]. An investigation of the
faecal carriage of ESBL-producing bacteria in both Primary
Health Care Units and in the University Hospital setting in
southern Sweden was conducted in 2008–2010. The only
species found was E. coli and the authors described the
prevalence as higher than expected in both groups; 2.1–3% and
1.8–6.8%, respectively [5]. A recent study from Uppsala
investigated the prevalence of EPE in healthy preschool
children compared with patients in the same age group. The
authors found a carrier rate of 2.9% in healthy children
compared with 8.4% in patients of the corresponding age
group [6].
In this study we present the epidemiology of ESBL-produc-
ing E. coli from the national surveillance system SmiNet and the
Swedish data from EARS-Net. In addition, we describe the
detailed molecular epidemiology and stability of resistance
genes and epidemiological strain types over time by examining
isolates from point prevalence studies performed in 2007,
2009 and 2011.
Materials and Methods
SmiNet for surveillance of pathogens regulated by the
Communicable Disease Act
Since 1 February 2007, EPE are notiﬁable for Swedish
laboratories according to the Communicable Disease Act.
Notiﬁcations are promptly made to the SmiNet database.
Since 2009, an extended deﬁnition of ESBL that includes all
b-lactamases with an extended spectrum and not only those
that are inhibited by clavulanic acid (referred to as ESBLA
according to Giske et al. [7]) is advocated in Sweden. As a
consequence Enterobacteriaceae with plasmid-mediated
AmpC enzymes (ESBLM) and carbapenemase enzymes
(ESBLCARBA) are also notiﬁable. Since 2012 clinical notiﬁcation
is required for Enterobacteriaceae with ESBLCARBA (or carb-
apenemase-producing Enterobacteriaceae).
The reporting to SmiNet uses a unique personal identiﬁ-
cation number issued to all Swedish residents that is used in all
contacts with the healthcare system. A case record is created
after the arrival of the ﬁrst notiﬁcation. Any subsequent
notiﬁcations are merged with the initial case record. The
epidemiological notiﬁcation form data are validated by SMI and
the local communicable disease act ofﬁcer. The validated
variables used in the study were age and gender. In this study,
SmiNet reporting of Enterobacteriaceae isolates producing
ESBLA or ESBLM from 2007, 2009 and 2011 were included.
Special attention has been given to analysis of the E. coli
isolates that dominate the materials.
Surveillance of invasive pathogens, the Swedish EARS-Net
cohort
At the SMI, national data are collected each year monitoring
invasive E. coli isolates. Each reporting laboratory regularly
submits data ﬁles containing gender, age, resistance proﬁle and
referring clinic. This data is also reported together with
invasive surveillance data on several other species to EARS-
Net which is a European surveillance system monitored by the
ECDC (European Centre for Disease Prevention and Control)
(http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/). In
Sweden the catchment population for the participating
laboratories has always exceeded 75% of the Swedish popu-
lation, and in 2011 it even exceeded 80% because of the
merging of a few laboratories, thereby increasing their
catchment population further.
Bacterial isolates
National point prevalence studies of consecutive ESBL-
producing E. coli isolated from urine were carried out
nationally in Sweden in 2007, 2009 and 2011). 20/21 of the
Swedish counties have participated in all three years. During
2007 isolates were collected during a 3-month period. As the
number of ESBL-producing E. coli was increasing rapidly we
adjusted the 2009 and 2011 collection periods to one month
only. This resulted in 236 isolates in 2007, 304 isolates 2009
and 463 isolates in 2011. The selection criteria for the isolates
were urinary E. coli resistant to cefadroxil (used in Sweden as a
screening marker for EPE), and resistance or intermediate
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susceptibility to cefotaxime and/or ceftazidime following
EUCAST guidelines (Clinical breakpoints-bacteria (v 3.1)
www.eucast.org). E. coli isolates positive in phenotypic tests
for ESBLA, ESBLM and ESBLCARBA (none in this collection)
constitute the ESBL-producing E. coli in this study.
Antimicrobial susceptibility testing
Susceptibility testing was performed by disc diffusion (Oxoid,
Basingstoke, UK) or Etest (bioMerieux, Marcy l’Etoile, France)
according to the EUCAST guidelines and breakpoints valid at
the time of testing. The agents tested were: cefadroxil,
cefotaxime, ceftazidime, mecillinam, piperacillin-tazobactam,
ciproﬂoxacin, trimethoprim, nitrofurantoin, gentamicin, tobra-
mycin and amikacin. In 2009 and 2011 also meropenem,
tigecycline and colistin were tested. In 2011 fosfomycin was
added to the test panel. Screening for ESBL-producing E. coli
was performed with combination disc testing using clavulanic
acid as inhibitor for blaCTX-M, blaSHV or blaTEM (Becton-
Dickinson, Cockeysville, MD, USA) and cloxacillin as inhibitor
for blaAmpC (Rosco Diagnostica A/S, Taastrup, Denmark).
Statistically signiﬁcant variations in antimicrobial suscepti-
bility test results between blaCTX-M-15 and other ESBL geno-
types were determined using Fisher’s exact test (p <0.05). A
non-parametric test for trend among ordered groups (exten-
sion of Wilcoxon rank-sum test) was used for trend analysis of
changes in median age. Calculations were done with STATA v.12
(StataCorp LP, TX, College Station, USA).
PCR detection and sequencing of ESBL genotypes
Phenotypic positive ESBL isolates were veriﬁed by screening for
blaCTX-M and acquired blaAmpC genes with real-time multiplex
PCR as previously described [8,9]. Standard PCR was used to
detect blaSHV and blaTEM [10] and was applied on all blaCTX-M
negative isolates that expressed an ESBL phenotype.
To amplify the genes before sequence analysis PCR was
performed using M13-tagged primers (IDT, Leuven, Belgium)
sequences stated below. AmpliTaq DNA Polymerase with
buffer II (Life Technologies, Stockholm, Sweden) was used for
standard PCR. The primers for ampliﬁcation of CMY-genes for
sequence analysis were CIT-F: ATGATGAAAAAATCGTT
ATGCTSC and CIT-R: CATGGGATTTTCCTTGCTGT. The
annealing temperature used was 55°C. AmpliTaq Gold 360
Master Mix (Life Technologies, Stockholm, Sweden) was used
for FAST PCR proceeding sequencing conducted for detection
of CTX-M genes. The primers used were: CTX-M-gr1-F:
CAGAATAAGGAATCCCATGGTT, CTX-M-gr1-R: GGCG
ATAAACAAAAACGGAAT [11], CTX-M-gr2-F: ATGATGA
CTCAGAGCCATTCG, CTX-M-gr2-R: TGGGTTACGATT
TTCGCC, CTX-M-gr9-F: ATGGTGACAAAGAGAG
TGCA, CTX-M-gr9-R: CCCTTCGGCGATGATTCTC [12].
The annealing temperature of all CTX-M ampliﬁcations was
60°C.
Sequence reactions, sample clean up and single read
sequencing were performed by GATC Biotech (Konstanz,
Germany). Universal M13 primers were used for all sequencing
reactions, M13-F: GTTTTCCCAGTCACGACGTTGTA,
M13-R: TTGTGAGCGGATAACAATTTC.
Pulsed-ﬁeld gel electrophoresis
Pulsed-ﬁeld gel electrophoresis (PFGE) analysis was performed
according to standard procedures [13,14]. Brieﬂy, XbaI-
digested DNA was electrophoresed in 1% agarose in 0.5 9
TBE at 14°C for 26 h, using the CHEF Mapper XA system
(Bio-Rad Laboratories, Hercules, CA, USA) set at 6 V/cm, with
pulse times linearly increased from 12 s initial switch time to
40 s ﬁnal switch time. XbaI-digested DNA from Salmonella
Braenderup H9812 was included as the normalization standard
on every gel. DNA banding patterns were analysed using the
BIONUMERICS software, version 6.6 (Applied Maths NV, Sint-
Martens-Latem, Belgium), choosing the Dice coefﬁcient for
calculating pairwise similarities and the UPGMA algorithm for
constructing dendrograms. Position tolerance and optimization
were both set at 1%. Bands within the size range 669–33 kb
were included in the analysis, and each indistinguishable banding
pattern (>90% pairwise Dice similarity) identiﬁed in at least two
unique isolates was assigned a PFGE pattern name [15].
Phylogenetic grouping
Phylotyping was performed using a triplex standard PCR
according to Clermont et al. [16]. The PCR products were
analysed using MULTINA (Shimadzu Corporation, Kyoto, Japan).
pabB screening and multilocus sequence typing
All isolates were subjected to pabB screening [17]. This PCR
method predicts the E. coli multilocus sequence typing (MLST)
type ST131. Representative isolates from the different PFGE
patterns (one or two depending on cluster size) were selected
for MLST according to the protocol developed by Wirth et al.
[18]. All PCR primers were tagged with M13 universal
sequences (the same as described above). Annealing temper-
atures were adjusted to 60°C. The MLST data analysis,
including sequence type assignment and minimal spanning trees
[18], was performed using BIONUMERICS v.6.6 and the MLST
online plug-in.
Results and Discussion
Summarized data on E. coli from the SmiNet and EARS-Net
surveillance systems are presented in Table 1. The data show
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that the number of EPE has been steadily increasing in Sweden,
mostly represented by ESBL-producing E. coli. Fig. 1 illustrates
the number of ESBL-producing E. coli cases in Sweden during
the selected time periods distributed by age categories. To be
able to interpret the ﬂuctuations seen correctly, the demo-
graphic age distributions for the same time periods are
included in the ﬁgure. In Fig. 1 we see a peak for acquisition of
ESBL-producing E. coli in women aged 20–30 years. This is
probably due to urinary tract infections being more common
in these ages and among women. This peak is seen in all three
time periods, but intensiﬁed over time, which indicates a trend
that coincides with EPE becoming more commonly commu-
nity-acquired [19]. This is also supported by Table 1, where it
is shown that the median age of acquiring ESBL-producing
E. coli is decreasing signiﬁcantly according to the trend analysis
(p <0.0001). There are several studies describing acquisition of
ESBL-producing E. coli during travel from Sweden to countries
of high endemicity [20,21]. The decreasing median age in
combination with reports of high prevalence in travellers
indicate that the typical patient with ESBL-producing E. coli is
shifting from multi-ill hospitalized patients to younger people
with no comorbidities, but with frequent travels to regions
were ESBL-producing E. coli are endemic.
Antimicrobial susceptibility testing
The susceptibility proﬁle of Swedish ESBL-producing E. coli was
stable over the three time periods (Table 2). Low resistance
rates were observed for mecillinam, nitrofurantoin and
amikacin. Nitrofurantoin and mecillinam are both recom-
mended treatment alternatives for uncomplicated urinary tract
infections in Sweden, and had very high activity also against the
circulating ESBL-producing E. coli clones in Sweden. Among the
aminoglycosides, amikacin was by far the drug with the highest
activity, and should be considered as the most appropriate
TABLE 1. Results from all reported cases of extended spectrum b-lactamase (ESBL) -producing Enterobacteriaceae in Sweden
during selected time-points
Surveillance system
2007 2009 2011
Women Men All Women Men All Women Men All
SmiNet
Total number of cases 1396 694 2098a 2413 1247 3691b 3699 1967 5666
Total number of E. coli cases 1171 516 1693 2125 1014 3160 3379 1689 5068
E. coli from urine 917 (78%) 294 (57%) 1214 (72%) 1683 (79%) 535 (53%) 2225 (70%) 2497 (74%) 796 (47%) 3293 (65%)
Invasive E. coli (blood and cerebrospinal ﬂuid) 34 (3%) 47 (9%) 81 (5%) 67 (3%) 83 (8%) 150 (5%) 101 (3%) 151 (9%) 252 (5%)
E. coli from screening (faeces and rectum) 144 (12%) 98 (19%) 242 (14%) 265 (12%) 246 (24%) 523 (15%) 556 (16%) 543 (32%) 1099 (22%)
Median age E. colid 60 63 62 55 64 59 50 64 57
EARS-Netc
E. coli 2049 1739 3788 2225 2057 4282 2688 2472 5160
E. coli ESBL 38 (2%) 47 (3%) 85 (2%) 49 (2%) 62 (3%) 111 (3%) 76 (3%) 109 (4%) 185 (4%)
aData missing for eight cases regarding gender.
bData missing for 31 cases regarding gender.
cThe EARS-Net data for E. coli have been revised and the numbers do not agree completely with the data on the ECDC website.
dStatistically signiﬁcant trend of decreasing median age (p <0.0001).
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FIG. 1. The incidence per age-category of extended spectrum b-lactamase (ESBL) -producing Escherichia coli. The demographic distribution of age in
Sweden is also illustrated for the same time periods.
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aminoglycoside for empiric treatment when targeting a
spectrum also covering ESBL-producing E. coli isolates. A slow
decline in resistance rates was seen for ciproﬂoxacin. The
trimethoprim resistance was high among the ESBL-producing
E. coli, around 70% (50–60% among ESBLM), which makes this
compound unsuitable for empirical treatment if such infections
are suspected. Ceftazidime susceptibility was 60–80% for
non-CTX-M-15 and acquired AmpC ESBL-producers, meaning
it could theoretically be a treatment alternative in a relatively
high number of patients. Generally there was a higher
resistance rate among blaCTX-M-15 producers than for the
other ESBL genotypes (Table 2).
ESBL genotypes
The ESBL genotypes were highly stable during the three time
periods (data not shown). The dominating genotype was
blaCTX-M-15. This genotype is reported to be the most
prevalent on all continents. The second most common
genotype is blaCTX-M-14, but the numbers are signiﬁcantly
lower in Sweden compared with blaCTX-M-15. The CTX-M
enzymes are assigned to phylogroups where blaCTX-M-15
belongs to phylogroup 1 and blaCTX-M-14 to phylogroup 9. In
Sweden 626 (62%) of all E. coli phenotypic positive ESBLA or
ESBLM isolates (n = 1003), have enzymes of phylogroup 1 and
209 isolates (21%) of phylogroup 9. One isolate had CTX-M
enzymes of both phylogroups 1 and 9 (blaCTX-M-15 and
blaCTX-M-14). Only two isolates belonged to the CTX-M
phylogroup 2 (blaCTX-M-2 genotype). In this collection we also
found 15 isolates (1%) that were blaSHV producers, blaSHV-12
being the most common. No blaTEM with extended-spectrum
activity were found.
Acquired plasmid-mediated AmpC production was seen in
50 isolates (5%), blaCMY-2 being the predominant type, which is
also in line with reports from most other countries [22–25]. In
the total collection, 86 isolates (9%) had putative chromosomal
AmpC (phenotypic AmpC-test positive, but negative in PCR
for plasmid-mediated AmpC) and were not deﬁned as
ESBLM-producers in this study [7]. Among all collected
isolates, 16 isolates (2%) were negative in both phenotypic
and genotypic ESBL tests.
Molecular epidemiology
Pulsed-ﬁeld gel electrophoresis was performed on all con-
ﬁrmed ESBL-producing isolates (n = 901) (Fig. 2a–c). The
typability of the strains was 94%. Among the isolates, 43%
were singletons. The most common PFGE-types were seen in
strains collected from all years and seem to be common types
circulating in Sweden. New types were only observed in low
numbers and differed between the collections. These are more
likely to be sporadic cases, which are less likely to persist in the
hospital environment. The high number of singletons conﬁrms
a high diversity among ESBL-producing E. coli in Sweden.
Multilocus sequence typing was performed on a subset of the
material. One or two isolates were selected from each
TABLE 2. Antimicrobial susceptibility and resistance in extended spectrum b-lactamase (ESBL) -producing Escherichia coli in
Sweden 2007, 2009 and 2011
Antimicrobial
Resistance (%) per year
2007 2009 2011
CTX-M-15
n = 136
Acquired
AmpC
n = 7
Other
ESBL
n = 70
CTX-M-15
n = 176
Acquired
AmpC
n = 16
Other
ESBL
n = 86
CTX-M-15
n = 250
Acquired
AmpC
n = 27
Other
ESBL
n = 132
Cefadroxil 136 (100) 7 (100) 70 (100) 176 (100) 16 (100) 86 (100) 250 (100) 27 (100) 132 (100)
Cefotaxime 136 (100) 6 (86) 69 (99) 176 (100) 16 (100) 86 (100) 250 (100) 27 (100) 131 (99)
Ceftazidime 129 (95) 7 (100) 12 (17) 158 (90) 16 (100) 18 (21) 228 (91) 27 (100) 49 (37)
Piperacillin-
tazobactam
2 (1) 4 (36) 1 (1) 46 (26) 4 (25) 7 (8) 45 (18) 4 (15) 9 (7)
Mecillinam 4 (3) 0 6 (8) 16 (9) 4 (25) 15 (17) 15 (6) 4 (15) 8 (6)
Ciproﬂoxacin 116 (85) 0 42 (60) 142 (81) 5 (31) 31 (36) 187 (75) 8 (30) 46 (35)
Gentamicin 45 (33) 1 (14) 22 (31) 81 (46) 2 (13) 36 (42) 118 (47) 6 (22) 35 (27)
Tobramycin 42 (31) 0 4 (6) 113 (64) 1 (6) 26 (30) 150 (60) 6 (22) 31 (23)
Amikacin 0 0 0 12 (7) 0 2 (2) 0 0 3 (2)
Nitrofurantoin 12 (9) 2 (29) 7 (10) 19 (11) 0 2 (2) 10 (4) 1 (4) 0
Trimethoprim 96 (71) 4 (57) 54 (77) 130 (74) 9 (56) 61 (71) 183 (73) 13 (48) 88 (67)
Meropenema NTc NT NT 0 0 0 0 0 0
Fosfomycinb NT NT NT NT NT NT 9 (4) 0 7 (5)
Tigecyclinea NT NT NT 0 0 0 0 0 1 (1)
Colistina NT NT NT 2 (1) 0 0 2 (1) 0 1 (1)
Aminoglycoside and
ﬂuoroquinolone
54 (40) 1 (14) 12 (17) 108 (61) 2 (13) 18 (21) 131 (52) 3 (11) 6 (5)
Other ESBLs include CTX-Ms other than CTX-M-15 and SHVs.
Bold face: Statistically signiﬁcant difference between prevalence of resistance in CTX-M-15 versus other summarized genotypes (p <0.05).
aOnly tested on the isolates from 2009 to 2011.
bOnly tested on the isolates from 2011.
cNT = not tested.
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PFGE-type depending on the size of the PFGE cluster. TheMLST
results were then extrapolated to the other isolates in the
respective PFGE cluster. The PFGE singletons were not tested.
However, the entire collection was subjected to PCR screening
for the speciﬁc pabB genotype that can predict inclusion in
ST131. Some PFGE singletons were found to be ST131. In total,
574 of 913 isolates were assigned to a sequence type.
The minimal spanning trees in Fig. 3(a–c) show the MLST
types in relation to year of isolation, resistance gene conferring
ESBL activity and phylogenetic grouping.
The MLST that clearly dominated in this Swedish material
was ST131 (Fig. 3a–c), including 34–38% of the isolates. This
percentage was stable over time. The other sequence types
found, representing 2–6%, of the isolates were ST38, ST69,
ST405, ST617 and ST648. There was no variation over time,
suggesting that the three collections indeed represent the
ESBL-producing E. coli circulating in Sweden.
Besides ST131, which is reported worldwide, ST38, ST405
and ST648 have been reported as some of the most common
sequence types in Canada [26]. A report from Belgium states
that ST131, ST617, ST48 (which is lacking completely in our
collection) and ST405 are the most common among ESBL-pro-
ducing E. coli [27]. ST617 is together with ST131 reported as
the predominant sequence type in Nigeria [28]. A recent
Danish study repored ST131 in 38% of the ESBL-producing
E. coli. They found the ST131 isolates associated with
community acquisition, with extensive virulence proﬁles and
having a great variety of capsular antigens [29]. In contrast, a
study from Minnesota (USA) describe ST131 as being health-
care-associated and mostly found in elderly hosts [30].
Phylogenetic grouping was, just like PFGE, performed on all
ESBL-conﬁrmed isolates (n = 913). This typing method assigns
E. coli to the phylogenetic groups A, B1, B2 and D. All strains
were typeable. In the entire point prevalence study collection
the B2 type dominated our material with 42–47% of the
isolates. Phylogroup D was the second most common, present
in 28–29% of the isolates. Phylogenetic group A was repre-
sented by 15–21% of the isolates and B1 by 9–10%. The
phylogenetic groups correlated to sequence type as shown in
Fig. 3(c). Isolates classiﬁed as phylogenetic group B2 have been
reported in strains with higher virulence [16]. It is further
supported by the fact that phylogenetic group B2 is almost the
only phylogenetic group seen among Swedish ST131 strains
(Fig. 3c). The distribution of ESBL-encoding genes is illustrated
in Fig. 4. The results were highly similar also when separating
the collections by year of isolation (data not shown).
Concluding Remarks
In this study we report that the number of ESBL-producing
E. coli is steadily increasing in Sweden. The combination of data
from the national reporting systems and from biannual point
prevalence studies provides a detailed overview of the ongoing
development. The genotypes and epidemiological strain types
were stable during the entire period of observation. The most
striking change was the decrease in median age of infected
which could possibly be explained by the general trends
observed in the world today, with increasing community
acquisition, and also acquisition during foreign travel.
2007 EC-05 EC-09
EC-11 EC-17
EC-18 EC-21
EC-27 EC-35
EC-44 like EC-65 like
EC-74 EC-81
EC-81 like EC-90 like
Singletons NT
2009 EC-05 EC-09
EC-11 EC-17
EC-18 EC-21
EC-27 EC-35
EC-44 like EC-65 like
EC-74 EC-81
EC-81 like EC-90 like
Singletons NT
2011 EC-05 EC-09
EC-11 EC-17
EC-18 EC-21
EC-27 EC-35
EC-44 like EC-65 like
EC-74 EC-81
EC-81 like EC-90 like
Singletons NT
(a)
(b)
(c)
FIG. 2. Circle diagrams illustrating pulsed ﬁeld gel electrophoresis
(PFGE) types in extended spectrum b-lactamase (ESBL) -producing
Escherichia coli from the three point prevalence collections. *Only the
most frequent PFGE types are named, all other PFGE types are
represented by ﬁve or more isolates in the same year.
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FIG. 3. Minimal-spanning tree (MST) of extended spectrum b-lactamase (ESBL) -producing Escherichia coli subjected to multilocus sequence typing.
Each circle corresponds to a sequence type (ST). The MST circle size is correlated to number of isolates included. The length and characteristic of the
lines connecting the circles correspond to the relationship between STs. Thick lines represent single-locus variants, thin lines correspond to
double-locus variants and broken lines describe three to seven allele differences between the sequence types. Grey ﬁelds surrounding the circles are
illustrating sequence types of the same clonal complex (cc). (a) MST describing ESBL-genotypes in association with sequence type. (b) MST illustrating
sequence types in relation to year of E. coli ESBL isolation. (c) MST illustrating phylogenetic groups among sequence types.
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